Wire · opportunities
Teva wins FDA approval for long-acting schizophrenia injection Weltruza
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
Teva has secured FDA approval for Weltruza, the first long-acting monthly subcutaneous injection of olanzapine for schizophrenia in the US, with sales starting soon. The drug showed symptom reduction and social functioning improvement in a Phase III trial and is under EMA review in Europe.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 20 sources have reported it between 9 Oct 2026 and 13 Oct 2026.
◆ ◆ The Wire takeaway
You can now target US healthcare providers with a new category of monthly schizophrenia treatment that improves patient compliance and convenience. European markets are opening soon, making it critical to prepare for cross-border launch strategies.
◆ Coverage
20 sources · first reported 9 Oct 2026 · latest 13 Oct 2026
◆ Topics